IMNM:NASDAQImmunome, Inc. Analysis

Immunome, Inc. (IMNM) is trading near its 20‑day SMA of 22.75 and above the 50‑day SMA of 22.00, indicating a short‑term bullish tilt despite a RSI of 31.9 that hints at oversold conditions. The MACD histogram remains negative (-0.36), suggesting lingering bearish momentum, yet volume is on an increasing trend and the price is holding above the identified support level of 19.82. Recent material news – a Phase 3 NDA submission for Varegacestat and an oral presentation of the RINGSIDE data at ASCO – provide a clear catalyst that could lift sentiment if the FDA response is favorable. The stock’s beta of 2.04 and 30‑day volatility of 43 % underscore heightened market sensitivity, while the company’s cash pile of $583 M versus modest debt offers a comfortable runway. Valuation metrics are mixed: a price‑to‑book of 3.8 appears reasonable, but a price‑to‑sales of 561× and a negative forward PE of -9.94 reflect earnings weakness. Analysts collectively rate the stock as a strong buy with a median target of $35, implying roughly 77 % upside from the current price of $19.90. The confluence of technical support, a potentially transformative FDA filing, and a sizable upside target makes IMNM a compelling speculative play, but investors must weigh the high beta, volatility, and the company’s ongoing operating losses.